FDA staff says safety issues with Biogen’s ALS drug to not prevent approval
By Bhanvi Satija (Reuters) -The U.S. health regulator’s staff said on Monday safety issues with Biogen Inc’s drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease, should not prevent its accelerated approval. A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday …
FDA staff says safety issues with Biogen’s ALS drug to not prevent approval Read More »









